Atlas Trials

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Clinical trial NCT07027748 · RECRUITING

Trial details

NCT number
NCT07027748
Sponsor
Steven DuBois, MD
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
NeuroblastomaNeuroblastoma RecurrentRelapsed NeuroblastomaRefractory Neuroblastoma
Start date
2025-06-27
Primary completion
2027-07-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.